Mast Cell Leukemia Clinical Trial
Official title:
A Phase 1 Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies
This is a Phase 1, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (also known as BLU-285), administered orally (PO), in adult patients with advanced systemic mastocytosis and other relapsed or refractory myeloid malignancies. The study consists of 2 parts:, dose-escalation (Part 1) and expansion (Part 2).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01807598 -
Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia
|
Phase 2 | |
| Terminated |
NCT00387426 -
Sunitinib in Treating Patients With Idiopathic Myelofibrosis
|
Phase 2 | |
| Completed |
NCT00898079 -
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer
|
||
| Active, not recruiting |
NCT03580655 -
(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
|
Phase 2 | |
| Completed |
NCT00112593 -
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
|
N/A | |
| Completed |
NCT00006251 -
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer
|
Phase 1/Phase 2 | |
| Terminated |
NCT02415608 -
Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis
|
Phase 2 | |
| Active, not recruiting |
NCT00118352 -
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
|
Phase 2 | |
| Completed |
NCT01869777 -
Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia
|
N/A | |
| Completed |
NCT01273766 -
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies
|
Phase 2 | |
| Completed |
NCT01231919 -
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
|
Phase 1 | |
| Terminated |
NCT03214666 -
GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT01199562 -
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
|
||
| Completed |
NCT00014235 -
Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies
|
N/A | |
| Completed |
NCT04695431 -
Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM
|
||
| Completed |
NCT00890747 -
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT01053494 -
Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer
|
N/A | |
| Available |
NCT05219266 -
Managed Access Programs for PKC412, Midostaurin
|